Outcomes in Patients With Poor-risk Cytogenetics With or Without TP53 Mutations Treated With Venetoclax and Azacitidine.
Daniel A PollyeaKeith W PratzAndrew H WeiVinod A PullarkatBrian A JonasChristian RecherSunil BabuAndre C SchuhMonique DailYan SunJalaja PotluriBrenda J ChylaCourtney D D DiNardoPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
In poor-risk cytogenetics+TP53mut patients, venetoclax+azacitidine improved remission rates but not DoR or OS compared to azacitidine alone. However,in poor-risk cytogenetics+TP53wt patients, venetoclax + azacitidine resulted in higher remission rates and longer DoR and OS than azacitidine alone, with outcomes comparable to similarly-treated patients with intermediate-risk cytogenetics. Toxicities were similar in TP53mut and TP53wt patients.